[A23-47] Olaparib (prostate cancer) – Addendum to Commission A23-03
Last updated 06.07.2023
Project no.:
A23-47
Commission:
Commission awarded on 23.05.2023 by the Federal Joint Committee (G-BA).
Report type:
Addendum
Status:
Commission completed
Department/Division:
Drug Assessment
Topic:
Cancer
Indication:
Adults with metastatic castration-resistant prostate cancer (mCRPC) in whom chemotherapy is not clinically indicated
Result of dossier assessment:
- Patients with treatment-naive mCRPC and BRCA mutation: hint of major added benefit
- Patients with treatment-naive mCRPC without BRCA mutation (BRCA wild type): hint of lesser benefit
- Patients with pretreated mCRPC: added benefit not proven
Note:
If the need for additional work on a project commissioned by the G-BA arises during consultations, then IQWiG presents a report in the form of an "addendum". The G-BA subsequently decides on the extent of the added benefit, thus completing the early benefit assessment.
| Project no. | Title | Status |
|---|---|---|
| A23-03 | Olaparib (prostate cancer) - Benefit assessment according to § 35a SGB V | Commission completed |
Federal Joint Committee (G-BA)
2023-07-06 A G-BA decision was published.